Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Aberrant expression of COT is related to recurrence of papillary thyroid cancer.

Lee J, Jeong S, Park JH, Lee CR, Ku CR, Kang SW, Jeong JJ, Nam KH, Shin DY, Lee EJ, Chung WY, Jo YS.

Medicine (Baltimore). 2015 Feb;94(6):e548. doi: 10.1097/MD.0000000000000548.

2.

No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma.

Kumagai A, Namba H, Takakura S, Inamasu E, Saenko VA, Ohtsuru A, Yamashita S.

Endocr J. 2006 Oct;53(5):615-20. Epub 2006 Aug 8.

3.

KSR1 is coordinately regulated with Notch signaling and oxidative phosphorylation in thyroid cancer.

Lee J, Seol MY, Jeong S, Kwon HJ, Lee CR, Ku CR, Kang SW, Jeong JJ, Shin DY, Nam KH, Lee EJ, Chung WY, Jo YS.

J Mol Endocrinol. 2015 Apr;54(2):115-24. doi: 10.1530/JME-14-0270. Epub 2015 Jan 21.

PMID:
25608512
4.

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW.

J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9. Epub 2005 Sep 20.

PMID:
16174717
5.

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.

Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE, Yip L.

Ann Surg Oncol. 2011 Dec;18(13):3566-71. doi: 10.1245/s10434-011-1781-5. Epub 2011 May 19.

PMID:
21594703
6.

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Xing M.

Endocr Rev. 2007 Dec;28(7):742-62. Epub 2007 Oct 16. Review.

PMID:
17940185
7.

BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.

Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C Jr, Knauf JA, Zhang L, Taira K, Fagin JA.

Endocrinology. 2006 Feb;147(2):1014-9. Epub 2005 Oct 27.

PMID:
16254036
8.

Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.

Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, Al-Sanea O, Al-Dayel F, Uddin S, Al-Kuraya KS.

J Clin Endocrinol Metab. 2008 Feb;93(2):611-8. Epub 2007 Nov 13.

PMID:
18000091
9.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

10.

The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.

Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK.

Clin Endocrinol (Oxf). 2006 Sep;65(3):364-8.

PMID:
16918957
11.

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA.

Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627. Epub 2010 Nov 24.

12.

MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.

Zhang X, Li D, Li M, Ye M, Ding L, Cai H, Fu D, Lv Z.

Int J Cancer. 2014 Jan 15;134(2):257-67. doi: 10.1002/ijc.28141. Epub 2013 Sep 18.

13.

Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.

Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M.

J Clin Endocrinol Metab. 2006 Sep;91(9):3667-70. Epub 2006 Jun 13.

PMID:
16772349
14.

Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.

Baitei EY, Zou M, Al-Mohanna F, Collison K, Alzahrani AS, Farid NR, Meyer B, Shi Y.

J Pathol. 2009 Apr;217(5):707-15. doi: 10.1002/path.2496.

PMID:
19156774
15.

BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.

Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R.

Endocr Relat Cancer. 2008 Jun;15(2):511-20. doi: 10.1677/ERC-07-0130.

PMID:
18509003
16.

The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry.

McKelvie PA, Chan F, Yu Y, Waring P, Gresshoff I, Farrell S, Williams RA.

Pathology. 2013 Dec;45(7):637-44. doi: 10.1097/PAT.0000000000000008.

PMID:
24247620
17.

BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients.

Pelttari H, Schalin-Jäntti C, Arola J, Löyttyniemi E, Knuutila S, Välimäki MJ.

APMIS. 2012 May;120(5):380-6. doi: 10.1111/j.1600-0463.2011.02844.x. Epub 2011 Nov 25.

PMID:
22515292
18.

High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.

Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA.

Cancer Res. 2003 Aug 1;63(15):4561-7.

19.

Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.

Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R.

Endocr Relat Cancer. 2006 Jun;13(2):455-64.

PMID:
16728573
20.

Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.

Buitrago D, Keutgen XM, Crowley M, Filicori F, Aldailami H, Hoda R, Liu YF, Hoda RS, Scognamiglio T, Jin M, Fahey TJ 3rd, Zarnegar R.

Ann Surg Oncol. 2012 Mar;19(3):973-80. doi: 10.1245/s10434-011-2029-0. Epub 2011 Aug 31.

PMID:
21879273

Supplemental Content

Support Center